Departments of Pathology.
Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, CA.
Am J Surg Pathol. 2018 Jul;42(7):855-865. doi: 10.1097/PAS.0000000000001053.
Eligibility for liver transplant is most commonly decided by measuring tumor size and number on radiographic imaging. However, this method often underestimates the extent of disease. Evaluation of tumor histology has been shown to improve risk stratification when compared with imaging-based transplant criteria, but the World Health Organization (WHO) guidelines for grading hepatocellular carcinoma (HCC) are imprecise and require subjective interpretation by the pathologist. We performed a retrospective analysis of 190 explanted livers containing HCC and correlated histologic features with posttransplant recurrence to formulate a three-tiered, point-based scoring system that categorizes tumors as having a low, intermediate, or high risk of recurrence. Our Recurrence Risk Assessment Score (RRAS) evaluates tumor architecture and specific cytologic features-nuclear pleomorphism, cytoplasmic amphophilia, and nuclear-to-cytoplasmic ratio-showing superior stratification of HCC recurrence risk compared with imaging criteria and grade assigned by WHO methodology. Stratifying tumors using RRAS criteria, the rate of recurrence after transplant was 0% among low-risk tumors (compared with 3% of well-differentiated tumors), 12% among intermediate-risk tumors (compared with 15% of moderately differentiated tumors), and 54% among high-risk tumors (compared with 29% of poorly differentiated tumors). Receiver operating characteristic analysis shows significantly improved performance of RRAS criteria in predicting HCC recurrence compared with WHO grade (area under curve of 0.841 and 0.671, respectively; P=0.0061). Our results indicate that evaluation of tumor histology offers superior prediction of recurrence risk following liver transplantation compared with radiographic criteria, and that the RRAS system better stratifies recurrence risk compared with HCC grading by WHO methodology.
肝移植的资格通常通过测量影像学上的肿瘤大小和数量来决定。然而,这种方法往往低估了疾病的程度。与基于影像学的移植标准相比,肿瘤组织学的评估已被证明可以改善风险分层,但世界卫生组织(WHO)肝细胞癌(HCC)分级指南不够精确,需要病理学家进行主观解释。我们对 190 例包含 HCC 的肝移植标本进行了回顾性分析,将组织学特征与移植后复发相关联,制定了一个三级、基于分数的评分系统,将肿瘤分为低、中、高复发风险。我们的复发风险评估评分(RRAS)评估肿瘤结构和特定细胞学特征-核多形性、细胞质嗜酸性和核质比-与影像学标准和 WHO 方法分级相比,显示出 HCC 复发风险分层的优越性。使用 RRAS 标准对肿瘤进行分层,移植后复发率在低风险肿瘤中为 0%(与高分化肿瘤的 3%相比),中风险肿瘤中为 12%(与中分化肿瘤的 15%相比),高风险肿瘤中为 54%(与低分化肿瘤的 29%相比)。受试者工作特征分析显示,RRAS 标准在预测 HCC 复发方面的表现明显优于 WHO 分级(曲线下面积分别为 0.841 和 0.671;P=0.0061)。我们的结果表明,与影像学标准相比,肿瘤组织学评估提供了更好的肝移植后复发风险预测,与 WHO 方法的 HCC 分级相比,RRAS 系统更好地分层了复发风险。